Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Given my DCF valuation putting a base case valuation of $78.35/share (157% upside from the $30.45 share price today) and the above disconnect in valuation to competitive obesity pipeline clinical stage biotechs, Viking Therapeutics appears to offer a fair/under value opportunity
However, most patients begin to see results around two to three months after starting the program
These external labs use state of the art instrumentation and validated methods to provide accurate compound characterization
Disclaimer This product is intended for laboratory research use only
Kidney Is it advisable to use Neurobion Forte RF Injection when experiencing kidney problems
US$ 28.54
US$ 29.01
US$ 29.94
US$ 23.57
US$ 21.78
US$ 23.70
US$ 29.25
